Thomas Ferkol, M.D.  ferkol_t@wustl.edu

Profile picture
Director, Division of Allergy, Immunology, and Pulmonary Medicine
Professor of Cell Biology and Physiology
Alexis Hartmann Professor of Pediatrics
Researcher, Pathobiology
Cell Biology & PhysiologyAllergy, Immunology and Pulmonary Medicine

phone: (314) 454-2694

Clinical Interests

Thomas Ferkol, MD is the Alexis Hartmann Professor of Pediatrics, Professor of Cell Biology and Physiology, and Director of the multidisciplinary Division of Pediatric Allergy, Immunology, and Pulmonary Medicine at the Washington University School of Medicine. Dr. Ferkol graduated from Case Western Reserve University (Cleveland, Ohio) in 1981, and he received his M.D. degree from the Ohio State University College of Medicine (Columbus, Ohio) in 1985. He was a pediatric resident at the University of North Carolina at Chapel Hill (1985-1988), where he also served as Chief Resident and Clinical Instructor (1988-1989). Dr. Ferkol returned to Case Western Reserve University in 1989 for fellowship training in pediatric pulmonology, and subsequently joined the faculty of Case Western Reserve University and Rainbow Babies and Children’s Hospital. Dr. Ferkol moved to Washington University School of Medicine in 2000, where he is currently Director of the Division of Pediatric Allergy, Immunology, and Pulmonary Medicine. He is the past director of the comprehensive Washington University Cystic Fibrosis Center, and directed premier clinical and research programs in cystic fibrosis. The Center is a member of the Cystic Fibrosis Foundation Therapeutics Development Network. An American Lung Association Edward Livingston Trudeau Scholar and recipient of the Cystic Fibrosis Foundation (CFF) LeRoy Matthew’s Physician-Scientist Award, his research has focused on characterizing genetic and molecular factors that contribute to lung disease in cystic fibrosis and primary ciliary dyskinesia. With past and continued support from the National Institutes of Health (NIH), CFF, and March of Dimes, Dr. Ferkol and his collaborators are studying the origins and potential therapeutic targets for these inherited airway diseases. He is an investigator for the NIH-supported Genetic Diseases of Mucociliary Clearance Consortium, and has assembled clinical, biomedical, and engineering research collaborative at Washington University, studying the genetic and phenotypic spectrum of ciliopathies. He is also co-principal investigator on a NIH-funded program that is examining adverse respiratory outcomes in children with chronic lung disease related to prematurity. Dr. Ferkol has been an active member of the American Thoracic Society (ATS), serving as the chair of the Scientific Assembly on Pediatrics and chair of its program committee. He was recently installed as president of the ATS, only the second pediatrician in the 110 years of the Society. He has been a member of several scientific review groups, including the NIH Gene and Drug Delivery Study Section, ATS Career Development Grants Review Committee, CFF Research Development Program Review Committee and CFF Functional Genomics Review Committee. Finally, he serves as a member of the American Board of Pediatrics Subboard of Pediatric Pulmonology.

Education

  • BA, magna cum laude, Case Western Reserve University1981
  • MB, University of Nottingham, School of Biological Sciences1980
  • MD, Medicinae doctor, The Ohio State University College of Medicine1985

Training

  • Intern, University of North Carolina at Chapel Hill1985 - 1986
  • Resident, University of North Carolina at Chapel Hill1986 - 1988
  • Chief Resident, University of North Carolina at Chapel Hill1988 - 1989
  • Pulmonology Fellow, Case Western Reserve University School of Medicine1989 - 1992

Licensure and Board Certification

  • Medical License, State of Missouri (current)
  • Medical License, State of North Carolina (expired voluntarily)
  • Medical License, State of Ohio (expired voluntarily)
  • National Board of Medical Examiners, Diplomate
  • US Drug Enforcement Agency, Certified
  • American Board of Pediatrics, General Pediatrics Diplomate, Certified (Re-certified, 1998, 2005) 1990
  • American Board of Pediatrics, Pediatric Pulmonology Subboard Diplomate (Re-certified, 2002, 2009) 1994

Honors

  • Cystic Fibrosis Foundation LeRoy Matthews Physician-Scientist Award1989
  • Floyd Denny Pediatric Alumni Society Award, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina1989
  • Rainbow Babies and Children’s Hospital Trustees New Investigator Award1992
  • American Lung Association Edward Livingston Trudeau Scholar1994
  • Teaching Excellence Award, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio1994
  • Society for Pediatric Research, member1997
  • Best Doctors of America®1998 - Pres
  • EDI Innovation Award.1999
  • European Cystic Fibrosis Conference Presentation Award2004
  • America's Top Pediatricians, Consumer's Research Council of America2006 - Pres
  • American Pediatric Society, member2009 - Pres
  • Alexis Hartmann MD Professorship Award2012

Recent Publications view all (148)


  1. Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;197(12):e24-e39. PMCID:PMC6006411  PMID:29905515 
  2. Functional characterization of biallelic RTTN variants identified in an infant with microcephaly, simplified gyral pattern, pontocerebellar hypoplasia, and seizures. Pediatr Res. 2018. PMID:29967526 
  3. Acute Responses to Diuretic Therapy in Extremely Low Gestational Age Newborns: Results from the Prematurity and Respiratory Outcomes Program Cohort Study. J Pediatr. 2018;197:42-47.e1. PMCID:PMC5970973  PMID:29599068 
  4. Advances in the Genetics of Primary Ciliary Dyskinesia: Clinical Implications. Chest. 2018. PMID:29800551 
  5. Electronic cigarette use in youths: a position statement of the Forum of International Respiratory Societies. Eur Respir J. 2018;51(5). PMID:29848575 
  6. Comment on: Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2018;65(1). PMID:28834235 
  7. Twenty Facts About Cystic Fibrosis. Am J Respir Crit Care Med. 2017;196(12):P23-P24. PMID:29243949 
  8. Growth and nutritional status, and their association with lung function: a study from the international Primary Ciliary Dyskinesia Cohort. Eur Respir J. 2017;50(6). PMID:29269581 
  9. Movement. Paediatr Respir Rev. 2017;24:19-20. PMID:28687245 
  10. Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low Gestational Age: A Prospective Cohort Study. J Pediatr. 2017;187:89-97.e3. PMCID:PMC5533632  PMID:28528221 
  11. Association of Antibiotics, Airway Microbiome and Inflammation in Infants with Cystic Fibrosis. Ann Am Thorac Soc. 2017;14:1548-1555. PMID:28708417 
  12. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax. 2017. PMID:28280235 
  13. Thoracoabdominal Asynchrony Is Not Associated with Oxyhemoglobin Saturation in Recovering Premature Infants. Neonatology. 2017;111(4):297-302. PMCID:PMC5443694  PMID:28013296 
  14. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Ann Am Thorac Soc. 2016;13(8):1305-13. PMID:27070726 
  15. Primary Ciliary Dyskinesia: First Health-related Quality of Life Measures for Pediatric Patients. Ann Am Thorac Soc. 2016. PMID:27464304 
  16. Primary ciliary dyskinesia and associated sensory ciliopathies. Expert Rev Respir Med. 2016;10(5):569-76. PMCID:PMC4893162  PMID:26967669 
  17. An Official American Thoracic Society Clinical Practice Guideline: Pediatric Chronic Home Invasive Ventilation. Am J Respir Crit Care Med. 2016;193(8):e16-35. PMID:27082538 
  18. Genetics and biology of primary ciliary dyskinesia. Paediatr Respir Rev. 2016;18:18-24. PMCID:PMC4864047  PMID:26476603 
  19. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol. 2016;51(2):115-32. PMCID:PMC4912005  PMID:26418604 
  20. Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016;169:116-21.e2. PMID:26388208 
  21. Decade of the lung--a call for action to promote lung health globally. Lancet Respir Med. 2016;4(1):e3-4. PMID:26762667 
  22. Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc. 2015;12(12):1822-30. PMCID:PMC4722827  PMID:26397992 
  23. Precision Medicine: At What Price? Am J Respir Crit Care Med. 2015;192(6):658-9. PMID:26207804 
  24. Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis. J Pediatric Infect Dis Soc. 2015;4(3):225-31. PMCID:PMC4554198  PMID:26336603 
  25. Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. Ann Am Thorac Soc. 2015;12(8):1170-6. PMCID:PMC4566413  PMID:26288390 
  26. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol. 2015;50(8):763-70. PMID:26061914 
  27. Such Are the Impositions of Quackery: E-Cigarettes. Ann Am Thorac Soc. 2015;12(6):787-8. PMID:26075549 
  28. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol. 2015;35(5):313-21. doi:10.1038/jp.2015.19  PMCID:PMC4414744  PMID:25811285 
  29. Ventilatory control and supplemental oxygen in premature infants with apparent chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2015;100(3):F233-7. doi:10.1136/archdischild-2014-307272  PMID:25716677 
  30. Official American Thoracic Society technical standards: flexible airway endoscopy in children. Am J Respir Crit Care Med. 2015;191(9):1066-80. doi:10.1164/rccm.201503-0474ST  PMID:25932763 
  31. Prematurity and respiratory outcomes program (PROP): study protocol of a prospective multicenter study of respiratory outcomes of preterm infants in the United States. BMC Pediatr. 2015;15(1):37. doi:10.1186/s12887-015-0346-3  PMCID:PMC4407843  PMID:25886363 
  32. Bronchiolitis obliterans syndrome is not specific for bronchiolitis obliterans in pediatric lung transplant. J Heart Lung Transplant. 2015;34(4):516-21. doi:10.1016/j.healun.2014.10.004  PMID:25499141 
  33. The Evolution of Cystic Fibrosis Care. Chest. 2015. doi:10.1378/chest.14-1997  PMID:25764168 
  34. Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2015. doi:10.1513/AnnalsATS.201412-596OC  PMID:25745825 
  35. Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. Am J Respir Crit Care Med. 2015;191(3):316-24. doi:10.1164/rccm.201409-1672OC  PMCID:PMC4351577  PMID:25493340 
  36. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol. 2015;50(1):42-8. doi:10.1002/ppul.23036  PMID:24644274 
  37. Response to Snijders et al. Pediatr Res. 2014;76(3):322. PMID:24933009 
  38. Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis. J Cyst Fibros. 2014;13(5):542-9. doi:10.1016/j.jcf.2014.06.005  PMID:25027419 
  39. Sources of methodological variability in phase angles from respiratory inductance plethysmography in preterm infants. Ann Am Thorac Soc. 2014;11(5):753-60. doi:10.1513/AnnalsATS.201310-363OC  PMID:24716708 
  40. L-plastin is essential for alveolar macrophage production and control of pulmonary pneumococcal infection. Infect Immun. 2014;82(5):1982-93. doi:10.1128/IAI.01199-13  PMCID:PMC3993441  PMID:24595139 
  41. The global burden of respiratory disease-impact on child health. Pediatr Pulmonol. 2014;49(5):430-4. doi:10.1002/ppul.23030  PMID:24610581 
  42. Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014;11 Suppl 3:S161-8. doi:10.1513/AnnalsATS.201312-444LD  PMID:24754825 
  43. Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. Am J Respir Crit Care Med. 2014;189(6):707-17. doi:10.1164/rccm.201311-2047OC  PMCID:PMC3983840  PMID:24568568 
  44. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11(3):404-6. doi:10.1513/AnnalsATS.201311-405PS  PMID:24673696 
  45. Laterality defects other than situs inversus totalis in primary ciliary dyskinesia: insights into situs ambiguus and heterotaxy. Chest. 2014. doi:10.1378/chest.13-1704  PMID:24577564 
  46. Picking up speed: advances in the genetics of primary ciliary dyskinesia. Pediatr Res. 2014;75(1-2):158-64. doi:10.1038/pr.2013.200  PMCID:PMC3946436  PMID:24192704 
  47. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc. 2013;10(6):574-81. doi:10.1513/AnnalsATS.201305-110OC  PMCID:PMC3960971  PMID:24024753 
  48. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013;68(12):1157-62. doi:10.1136/thoraxjnl-2013-203204  PMID:23704228 
  49. FDG PET imaging in cystic fibrosis. Semin Nucl Med. 2013;43(6):412-9. doi:10.1053/j.semnuclmed.2013.06.002  PMID:24094708 
  50. Mutations in SPAG1 cause primary ciliary dyskinesia associated with defective outer and inner dynein arms. Am J Hum Genet. 2013;93(4):711-20. doi:10.1016/j.ajhg.2013.07.025  PMCID:PMC3791252  PMID:24055112 
  51. Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia. Am J Hum Genet. 2013;93(4):672-86. doi:10.1016/j.ajhg.2013.08.015  PMCID:PMC3791264  PMID:24094744 
  52. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr. 2013;163(4):1152-7.e2. doi:10.1016/j.jpeds.2013.05.013  PMCID:PMC4064589  PMID:23810128 
  53. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol. 2013;48(10):943-53. doi:10.1002/ppul.22693  PMCID:PMC4059359  PMID:23818295 
  54. CCDC65 mutation causes primary ciliary dyskinesia with normal ultrastructure and hyperkinetic cilia. PLoS One. 2013;8(8):e72299. doi:10.1371/journal.pone.0072299  PMCID:PMC3753302  PMID:23991085 
  55. ZMYND10 is mutated in primary ciliary dyskinesia and interacts with LRRC6. Am J Hum Genet. 2013;93(2):336-45. doi:10.1016/j.ajhg.2013.06.007  PMCID:PMC3738827  PMID:23891469 
  56. Primary ciliary dyskinesia-causing mutations in Amish and Mennonite communities. J Pediatr. 2013;163(2):383-7. doi:10.1016/j.jpeds.2013.01.061  PMCID:PMC3725203  PMID:23477994 
  57. Identifying the origins of cystic fibrosis lung disease. N Engl J Med. 2013;368(21):2026-8. doi:10.1056/NEJMe1303487  PMID:23692172 
  58. Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms. Hum Mutat. 2013;34(3):462-72. doi:10.1002/humu.22261  PMCID:PMC3630464  PMID:23255504 
  59. Exome sequencing identifies mutations in CCDC114 as a cause of primary ciliary dyskinesia. Am J Hum Genet. 2013;92(1):99-106. doi:10.1016/j.ajhg.2012.11.003  PMCID:PMC3542458  PMID:23261302 
  60. LRRC6 mutation causes primary ciliary dyskinesia with dynein arm defects. PLoS One. 2013;8(3):e59436. doi:10.1371/journal.pone.0059436  PMCID:PMC3602302  PMID:23527195 
  61. The impact of the Clean Air Act. J Pediatr. 2012;161(5):781-6. doi:10.1016/j.jpeds.2012.06.064  PMID:22920509 
  62. Whole-exome capture and sequencing identifies HEATR2 mutation as a cause of primary ciliary dyskinesia. Am J Hum Genet. 2012;91(4):685-93. doi:10.1016/j.ajhg.2012.08.022  PMCID:PMC3484505  PMID:23040496 
  63. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros. 2012;11(5):446-53. doi:10.1016/j.jcf.2012.04.003  PMID:22554417 
  64. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet. 2012;44(8):886-9. doi:10.1038/ng.2344  PMCID:PMC3702264  PMID:22772370 
  65. Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med. 2012;185(10):1096-103. doi:10.1164/rccm.201111-2065OC  PMID:22403801 
  66. Mutations of DNAH11 in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. Thorax. 2012;67(5):433-41. doi:10.1136/thoraxjnl-2011-200301  PMID:22184204 
  67. Ciliopathies: the central role of cilia in a spectrum of pediatric disorders. J Pediatr. 2012;160(3):366-71. doi:10.1016/j.jpeds.2011.11.024  PMCID:PMC3282141  PMID:22177992 
  68. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol. 2012;47(2):125-34. doi:10.1002/ppul.21525  PMCID:PMC3214247  PMID:21830317 
  69. Recurrent pleural effusion without intrathoracic migration of ventriculoperitoneal shunt catheter: a case report. Pediatr Pulmonol. 2012;47(1):91-5. doi:10.1002/ppul.21510  PMID:22170808 
  70. Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr. 2011;159(5):819-824.e1. doi:10.1016/j.jpeds.2011.05.005  PMID:21705017 
  71. The emerging genetics of primary ciliary dyskinesia. Proc Am Thorac Soc. 2011;8(5):430-3. doi:10.1513/pats.201103-023SD  PMCID:PMC3209577  PMID:21926394 
  72. Effect of polarized release of CXC-chemokines from wild-type and cystic fibrosis murine airway epithelial cells. Am J Respir Cell Mol Biol. 2011;45(2):221-8. doi:10.1165/rcmb.2009-0249OC  PMCID:PMC3266059  PMID:20639462 
  73. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis Archives of Pediatrics and Adolsescent Medicine. 2011;165(847):856. 
  74. Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: a multicenter experience. Pediatr Pulmonol. 2011;46(483):488. doi:10.1002/ppul.21402  PMID:21284095 
  75. Hitting the target: new treatments for cystic fibrosis. Am J Respir Crit Care Med. 2010;182(12):1460-1. doi:10.1164/rccm.201008-1311ED  PMID:21159902 
  76. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol. 2010;45(9):934-44. doi:10.1002/ppul.21279  PMID:20597081 
  77. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182(3):298-306. doi:10.1164/rccm.201002-0157OC  PMID:20675678 
  78. Primary ciliary dyskinesia in Amish communities. J Pediatr. 2010;156(6):1023-5. doi:10.1016/j.jpeds.2010.01.054  PMCID:PMC2875274  PMID:20350728 
  79. IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia. Gene Ther. 2010;17(5):567-76. doi:10.1038/gt.2010.28  PMID:20357828 
  80. Airway proteins involved in bacterial clearance susceptible to cathepsin G proteolysis. Eur Respir J. 2010;35(2):410-7. doi:10.1183/09031936.00020809  PMCID:PMC2818476  PMID:19679607 
  81. Pediatric respiratory medicine--an international perspective. Pediatr Pulmonol. 2010;45(1):14-24. doi:10.1002/ppul.21165  PMID:20014351 
  82. Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2010;54(1):154-7. doi:10.1002/pbc.22283  PMID:19760774 
  83. NHLBI training workshop report: The vanishing pediatric pulmonary investigator and recommendations for recovery. Pediatr Pulmonol. 2010;45(1):25-33. doi:10.1002/ppul.21155  PMID:20025052 
  84. Aquagenic wrinkling of the palms in cystic fibrosis: comparison with controls and genotype-phenotype correlations. Arch Dermatol. 2009;145(11):1296-9. doi:10.1001/archdermatol.2009.260  PMID:19917960 
  85. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr. 2009;155(5):634-9.e1-4. doi:10.1016/j.jpeds.2009.04.059